Open Access

18F‑FDG‑PET/CT‑guided intensity‑modulated radiotherapy for 42 FIGO III/IV ovarian cancer: A retrospective study

  • Authors:
    • Ya‑Zheng Dang
    • Xin Li
    • Yu‑Xin Ma
    • Xiao‑Long Li
    • Ting Yang
    • Wan‑Ling Lu
    • Shi‑Gao Huang
  • View Affiliations

  • Published online on: October 19, 2018     https://doi.org/10.3892/ol.2018.9601
  • Pages: 149-158
  • Copyright: © Dang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of the present study was to evaluate the curative effect of fludeoxyglucose‑positron emission tomography/computed tomography (18F‑FDG‑PET/CT)‑guided intensity‑modulated radiotherapy (IMRT) for 42 patients with International Federation of Gynecology and Obstetrics (FIGO) stage III/IV ovarian cancer. Between January 2012 and December 2015, 42 patients with FIGO stage III/IV ovarian cancer who were treated with 18F‑FDG‑PET/CT‑guided IMRT at the Department of Radiation Oncology were analyzed. A total of 21 patients who exhibited recurrence following surgery and 11 patients who were unable to tolerate or rejected surgery received 5‑10 cycles of chemotherapy only. A total of 10 patients, who were either older (>70 years) or in poor general health were unable to undergo surgery and only received IMRT. The patients received a total radiation dose of 5,040 cGy (range, 4,500‑5,500 cGy), with a dose fraction of 200 cGy/fx, administered a total of 10‑14 times, 5 times/week, prior to being rested for half an hour to relocate lesions and undergoing a second round of radiotherapy for 10‑14 cycles. The 1‑, 2‑ and 3‑year progression‑free survival (PFS) rates of the patients were 66.7, 33.3 and 21.4%, respectively, and the median PFS time was 20.3 months. The 1‑, 2‑ and 3‑year local control rates of the patients were 90.5, 83.3 and 69.0%, respectively, and the 1‑, 2‑ and 3‑year overall survival (OS) rates were 73.8, 64.3 and 52.4%, respectively. According to the results of multivariate analysis using the Cox proportional hazards model, the Karnofsky performance status (KPS) score (1) was the only index associated with prognosis (P<0.003). The study concluded that for patients with advanced ovarian cancer, particularly for patients unable to undergo surgery or chemotherapy, 18F‑FDG PET/CT‑guided IMRT is a safe and effective treatment method, and it may be considered as an equally effective treatment option. Furthermore, the results of the present study suggested that the KPS score of a patient is the only factor affecting the OS time.
View Figures
View References

Related Articles

Journal Cover

January-2019
Volume 17 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Dang YZ, Li X, Ma YX, Li XL, Yang T, Lu WL and Huang SG: 18F‑FDG‑PET/CT‑guided intensity‑modulated radiotherapy for 42 FIGO III/IV ovarian cancer: A retrospective study. Oncol Lett 17: 149-158, 2019
APA
Dang, Y., Li, X., Ma, Y., Li, X., Yang, T., Lu, W., & Huang, S. (2019). 18F‑FDG‑PET/CT‑guided intensity‑modulated radiotherapy for 42 FIGO III/IV ovarian cancer: A retrospective study. Oncology Letters, 17, 149-158. https://doi.org/10.3892/ol.2018.9601
MLA
Dang, Y., Li, X., Ma, Y., Li, X., Yang, T., Lu, W., Huang, S."18F‑FDG‑PET/CT‑guided intensity‑modulated radiotherapy for 42 FIGO III/IV ovarian cancer: A retrospective study". Oncology Letters 17.1 (2019): 149-158.
Chicago
Dang, Y., Li, X., Ma, Y., Li, X., Yang, T., Lu, W., Huang, S."18F‑FDG‑PET/CT‑guided intensity‑modulated radiotherapy for 42 FIGO III/IV ovarian cancer: A retrospective study". Oncology Letters 17, no. 1 (2019): 149-158. https://doi.org/10.3892/ol.2018.9601